男性不育与男性特异性恶性肿瘤的关联:基于人群的回顾性队列研究的系统评价与Meta分析
该系统评价与Meta分析纳入6项基于人群的回顾性队列研究,评估男性不育与睾丸癌或前列腺癌发病风险的关联。4项研究分析睾丸癌(n=161,634;174例睾丸癌),合并RR为2.033(95%CI 1.66-2.48),异质性I²=1.55%;4项研究分析前列腺癌(n=183,950;377例前列腺癌),合并RR为1.68(95%CI 1.17-2.4),异质性I²=87.1%。男性不育与后续睾丸癌和前列腺癌风险均相关,但临床意义尚不确定。
要点
- 男性不育与后续睾丸癌风险相关,合并RR为2.033(95%CI 1.66-2.48),异质性I²=1.55%。
- 男性不育与后续前列腺癌风险相关,合并RR为1.68(95%CI 1.17-2.4),异质性I²=87.1%。
- 作者认为这些发现的临床意义仍不确定,未来研究应评估潜在机制以确定是否应改变男性不育者的睾丸和前列腺筛查实践。
核心结论
- 男性不育与后续睾丸癌和前列腺癌风险均相关。
- 这些发现的临床意义仍不确定,未来研究应评估潜在机制以确定是否应改变男性不育者的睾丸和前列腺筛查实践。
研究设计与样本
- 基于人群的回顾性队列研究的系统评价与Meta分析。
- 共纳入6项符合纳入标准的研究并进行批判性审查。
- 4项研究分析男性不育与睾丸癌(n=161,634;174例睾丸癌),4项研究分析不育与前列腺癌(n=183,950名男性;377例前列腺癌),研究时间覆盖1963年至2014年。
- 主要结局指标为男性因素不育者与生育对照人群的合并风险比(RR)差异,并按基线年龄、平均随访时间、研究时间范围和发表年份进行Meta回归分析。
- 注册号:PROSPERO 167277。
主要发现
- 睾丸癌:合并RR为2.033(95%CI 1.66-2.48);异质性Q=3.04(自由度df=3),I²=1.55%。
- 前列腺癌:合并RR为1.68(95%CI 1.17-2.4);异质性Q=23.3(df=3),I²=87.1%。
临床怎么用
- 作者认为这些发现的临床意义仍不确定,未来研究应评估潜在机制以确定是否应改变男性不育者的睾丸和前列腺筛查实践。
局限性
- 作者指出这些发现的临床意义仍不确定。
- 前列腺癌分析异质性I²=87.1%。
- 作者提出未来研究应评估潜在机制以确定是否应改变男性不育者的睾丸和前列腺筛查实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the current evidence that correlates impaired male fertility with the risk of developing male-related malignancies. DESIGN: Systematic review and meta-analysis of population-based retrospective cohort studies. SETTING: Not applicable. PATIENT(S): Men diagnosed with impaired fertility status and subsequently observed to determine incidence risk in developing testicular cancer (TCa) or prostate cancer (PCa). INTERVENTION(S): Not applicable. MAIN OUTCOME MEASURE(S): Pooled risk ratio (RR) differences among male factor infertility subjects compared with a fertile control population, and meta-regression analysis according to age at baseline, mean follow-up, range of study time, and year of publication. RESULT(S): Six studies met the inclusion criteria and were critically examined. Four studies examined male infertility and TCa (n = 161,634; 174 TCa cases), and four examined infertility in relation to PCa (n = 183,950 men; 377 PCa cases) from 1963 to 2014. The pooled RR was 2.033 (95% confidence interval [CI], 1.66-2.48); heterogeneity: Q = 3.04 (degree of freedom [df] = 3); I2 = 1.55% for TCa and 1.68 (95% CI, 1.17-2.4); Q = 23.3(df = 3); I2 = 87.1% for PCa. CONCLUSION(S): Male infertility was associated with a subsequent risk of both TCa and PCa. Although the clinical significance of these findings remains uncertain, future studies should evaluate the underlying mechanisms to determine whether testis and prostate screening practices should be altered in men with male infertility. CLINICAL TRIAL REGISTRATION NUMBER: PROSPERO 167277.
引用
- Del Giudice F, Kasman AM, De Berardinis E, et al. Association between male infertility and male-specific malignancies: systematic review and meta-analysis of population-based retrospective cohort studies. Fertil Steril. 2020. PMID: 32709378. doi:10.1016/j.fertnstert.2020.04.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。